Shield Therapeutics plc (SHIEF) Research

Shield Therapeutics plc operates as a specialized pharmaceutical firm, dedicated to developing and bringing to market advanced clinical therapies that address significant unfulfilled medical requirements. Its flagship product, Accrufer/Feraccru, offers an innovative, non-salt-based oral treatment specifically for adults suffering from iron deficiency, irrespective of whether anemia is present. Furthermore, the company is advancing PT20, a pioneering iron-based phosphate binder that has successfully concluded its pivotal Phase II trials for managing hyperphosphatemia in individuals with chronic kidney disease. This enterprise was founded in 2008 and maintains its headquarters in Gateshead, United Kingdom.

Market snapshot

Symbol
SHIEF
Price
$0.08
Day change
0.00%
Market cap
$92.0M
P/E ratio
-5.02x
52-week range
0.0346-0.1679
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Next earnings
in 3 months

Recent news

  • Shield Therapeutics drops as CFO exits and Medicaid concerns weigh

    Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported first-quarter revenue growth and positive earnings but...

Peer companies

  • BioSyent Inc. (BIOYF)
  • Green Growth Brands Inc. (GGBXF)
  • Grown Rogue International Inc. (GRUSF)
  • HLS Therapeutics Inc. (HLTRF)
  • Jushi Holdings Inc. (JUSHF)
  • Kintor Pharmaceutical Limited (KNTPF)
  • Cannara Biotech Inc. (LOVFF)
  • Orexo AB (publ) (ORXOF)

Open Shield Therapeutics plc (SHIEF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.